A few desperately ill patients have managed to get into clinical trials at the National Institutes of Health's famed hospital, even though the government's partial shutdown has others being turned away, the agency said. Normally, about 200 new patients every week enroll in studies at the NIH's research-only hospital, often referred to as the "house of hope" because so many of those people have failed standard treatments.
Gilead Sciences said Wednesday it stopped a late-stage clinical trial of a cancer treatment because it was clear the drug was working. Gilead was studying idelalisib as a treatment for chronic lymphocytic leukemia. The company said an early analysis of data from the study showed that patients who were treated with idelalisib had a longer time before the resumption of disease progression or death.
You might not think to look to a urine test to diagnose an eye disease. But a new Duke Univ. study says it can link what is in a patient's urine to gene mutations that cause retinitis pigmentosa, or RP, an inherited, degenerative disease that results in severe vision impairment and often blindness.
Chemists at The Scripps Research Institute have devised a new technique for connecting drug molecules to antibodies to make advanced therapies. Antibody-drug conjugates are the basis of new therapies on the market that use the target-recognizing ability of antibodies to deliver drug payloads to specific cell types. The new technique allows drug developers to forge more stable conjugates than are possible with current methods.
A tag team of two bacteria, one of them genetically modified, has a good chance to reduce or even eliminate the deadly disease African trypanosomiasis, or sleeping sickness, researchers at Oregon State Univ. conclude in a recent mathematical modeling study. African trypanosomiasis, caused by a parasite carried by the tsetse fly, infects 30,000 people in sub-Saharan Africa each year and is almost always fatal without treatment.
A global hunt for genes that influence heart disease risk has uncovered 157 changes in human DNA that alter the levels of cholesterol and other blood fats—a discovery that could lead to new medications. Each of the changes points to genes that can modify levels of cholesterol and other blood fats and are potential drug targets.
Hold your nose and don't spit out your coffee: Doctors have found a way to put healthy people's poop into pills that can cure serious gut infections—a less yucky way to do "fecal transplants." Canadian researchers tried this on 27 patients and cured them all after strong antibiotics failed to help.
They were mystery diseases that had stumped doctors for years—adults with strange symptoms and children with neurological problems, mental slowness or muscles too weak to let them stand. Now scientists say they were able to crack a quarter of these cases by decoding the patients' genes. Their study is the first large-scale effort to move gene sequencing out of the lab and into ordinary medical care.
Scientists have discovered a natural temperature sensor in a type of bacteria that causes meningitis and sepsis. The sensor allows the bacteria to evade the body’s immune response, leading to life-threatening infections. The Oxford Univ. team found that increasing temperature causes the bacteria to make more of a protective layer that surrounds the bacterium like an 'invisibility cloak' and helps it evade detection by the immune system.
Many viruses infect humans through mucosal surfaces. To help fight these viruses, scientists are working on vaccines that can establish a defense at mucosal surfaces. Vaccines can be delivered to the lungs via an aerosol spray, but are often cleared away before they can provoke an immune response. To overcome that, engineers have developed a new type of nanoparticle that protects the vaccine long enough to generate a strong immune response.
Researchers at The Scripps Research Institute discovered that an antibody that binds and neutralizes HIV likely also targets the body’s own “self” proteins. This finding could complicate the development of HIV vaccines designed to elicit this protective antibody, called 4E10, and others like it, as doing so might be dangerous or inefficient.
Pinning down an effective way to combat the spread of HIV, the viral precursor to AIDS, has long been a challenge for scientists and physicians, because the virus is an elusive one that mutates frequently and, as a result, quickly becomes immune to medication. A team of Drexel Univ. researchers is trying to get one step ahead of the virus with a microbicide they’ve created that can trick HIV into “popping” itself into oblivion.
A Lawrence Livermore National Laboratory-developed biological detection technology has been employed as part of an international collaboration that has detected a virus in bladder cancers. The research is believed to be the first study to demonstrate an association between Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8, and bladder cancers.
New research suggests it might be possible to spot early signs of multiple sclerosis in patients' spinal fluid, findings that offer a new clue about how this mysterious disease forms. The study released Tuesday was small and must be verified by additional research. But if it pans out, the finding suggests scientists should take a closer look at a different part of the brain than is usually linked to MS.
Yale Univ. School of Medicine researchers have discovered a protein that is the missing link in the complicated chain of events that lead to Alzheimer’s disease. They report the discovery in Neuron. Researchers also found that blocking the protein with an existing drug can restore memory in mice with brain damage that mimics the disease.
Flu vaccination is no longer merely a choice between a jab in the arm or a squirt in the nose. This fall, some brands promise a little extra protection. For the first time, certain vaccines will guard against four strains of flu rather than the usual three. Called quadrivalent vaccines, these brands may prove more popular for children than their parents. That's because kids tend to catch the newly added strain more often.
Scientists have found a compelling clue in the quest to learn what causes age-related memory problems. Wednesday's report offers evidence that age-related memory loss really is a distinct condition from pre-Alzheimer's—and offers a hint that what we now consider the normal forgetfulness of old age might eventually be treatable.
A new genome-wide association study (GWAS) estimates the number of different places in the human genome that are involved in schizophrenia. In particular, the study identifies 22 locations, including 13 that are newly discovered, that are believed to play a role in causing schizophrenia.
Univ. of California, Irvine infectious disease researchers have uncovered components of the SARS coronavirus that allow it to take over host cells in order to replicate. This insight is critical for a full understanding of any outbreaks caused by such viruses and may prove beneficial in the development of therapies not only for human coronavirus infections but for other pathogenic illnesses as well.
By any measure, tuberculosis (TB) is a wildly successful pathogen. It infects as many as two billion people in every corner of the world, with a new infection of a human host estimated to occur every second. Now, thanks to a new analysis of dozens of tuberculosis genomes gathered from around the world, scientists are getting a more detailed picture of why TB is so prevalent and how it evolves to resist countermeasures.
Anxiety disorders affect 40 million American adults in a given year. Currently available treatments, such as antianxiety drugs, are not always effective and have unwanted side effects. To develop better treatments, a more specific understanding of the brain circuits that produce anxiety is necessary. Researchers have now discovered a communication pathway between the amygdala and the ventral hippocampus that appears to control anxiety.
A new study by Rice Univ. biophysicists offers the most comprehensive picture yet of the molecular-level action of melittin, the principal toxin in bee venom. The research could aid in the development of new drugs that use a similar mechanism as melittin’s to attack cancer and bacteria.
Shares of Immunomedics jumped Wednesday after announcing that its treatment for a type of non-Hodgkin lymphoma helped to extend the lives of patients that used it in combination with another drug. The company said patients with newly diagnosed follicular lymphoma responded well to a combination of its epratuzumab and Roche's drug, Rituxan.
A new study from an international team led by Oak Ridge National Laboratory is guiding drug designers toward improved pharmaceuticals to treat HIV. The scientists used neutrons and x-rays to study the interactions between HIV protease, a protein produced by the HIV virus, and an antiviral drug commonly used to block virus replication.
For cancer patients, it’s not the primary tumor that is deadly, but the spread or “metastasis” of cancer cells from the primary tumor to secondary locations throughout the body that is the problem. That’s why a major focus of contemporary cancer research is how to stop or fight metastasis. Studies suggest that metastasizing cancer cells undergo a major molecular change when they leave the primary tumor—a process called EMT.